ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
clinical trial
Press Enter · cited answer in seconds
0 sources
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
Summary
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness is a clinical trial[1].
Key Facts
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness is located in Abilify in Bipolar Disorder for Long-term Effectiveness — located in the administrative territorial entity (P131): Hong Kong[2].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness is in the country of Abilify in Bipolar Disorder for Long-term Effectiveness — country (P17): Philippines[3].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness is in the country of Abilify in Bipolar Disorder for Long-term Effectiveness — country (P17): Taiwan[4].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness is in the country of Abilify in Bipolar Disorder for Long-term Effectiveness — country (P17): Thailand[5].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's instance of is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — instance of (P31): clinical trial[6].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's start time is recorded as +2007-10-31T00:00:00Z[7].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's end time is recorded as +2011-11-30T00:00:00Z[8].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's main subject is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — main subject (P921): bipolar disorder[9].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's number of participants is recorded as {'unit': '1', 'amount': '+127'}[10].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's title is recorded as A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder[11].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's short name is recorded as ABLE[12].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[13].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's ClinicalTrials.gov ID is recorded as NCT00484471[14].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}[15].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research intervention is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research intervention (P4844): aripiprazole[16].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research intervention is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research intervention (P4844): valproic acid[17].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's clinical trial phase is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — clinical trial phase (P6099): phase IV clinical trial[18].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research site is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research site (P6153): Castle Peak Hospital[19].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research site is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research site (P6153): Philippine General Hospital[20].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research site is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research site (P6153): Tri-Service General Hospital[21].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's research site is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — research site (P6153): Siriraj Hospital[22].
- ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness's study type is recorded as Abilify in Bipolar Disorder for Long-term Effectiveness — study type (P8363): interventional study[23].